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Abstract 
 
The use of lentiviral vectors based on the Human immunodeficiency virus 1 in gene 
therapy clinical trials has been growing due to their ability to transduce and permanently modify 
both dividing and non-dividing cells and their integration pattern considered to be safer relatively 
to that of gammaretroviral vectors. To take advantage of the full potential of lentiviral vectors for 
gene therapy applications, stable producer cell lines are desirable. However, its development has 
been hampered by the cytotoxicity of some viral components, namely the viral protease.  
In this work, a genetically modified and less toxic protease was evaluated for lentiviral 
vector production. Although less cytotoxic, this modified protease exhibits reduced proteolytic 
activity. While for envelope glycoproteins which do not require proteolytic processing – like VSV-
G – reduced protease activity did not impact vector titers, the conjugation of this protease with 
envelope glycoproteins typically used in stable cell line development – 4070A, GaLV10A1 and 
RD114A – resulted in reduced titers. Therefore, we have engineered the cleavage site of the HIV-
1 protease in these envelope glycoproteins. Engineering the protease cleavage site in GaLV10A1 
allowed rescuing viral titers to similar levels of those obtained with the wild-type HIV-1 protease 
in a transient transfection production, with a 5.5- to 36.7-fold increase. The engineered envelope 
glycoproteins are now being implemented in stable producer cell lines, expressing the modified 
protease. 
This work contributes for the development of a novel stable packaging cell line for 
continuous lentiviral vectors production, pioneering the use of a modified protease and providing 
new chimeric envelope glycoproteins, namely GaLV10A1giflet. Additionally, this thesis opened the 
door for the use of a novel high-titer envelope glycoprotein – GaLV10A1ΔR – for development of 
stable producer cell lines by cell receptor knock out strategy. 
 
 
 
 
 
 
 
 
 
 
Keywords: Lentiviral vectors; Modified HIV-1 protease; Envelope glycoprotein engineering; 
Packaging cell lines. 
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Resumo 
 
O uso de vetores lentivirais baseados no Vírus da imunodeficiência humana em ensaios 
clínicos de terapia génica tem vindo a aumentar devido à sua capacidade de transduzir e 
modificar permanentemente tanto células não quiescentes como quiescentes, e ao seu padrão 
de integração considerado mais seguro do que o dos vetores retrovirais. Para tirar partido de 
todo o potencial destes vetores em terapia génica, são desejáveis linhas celulares produtoras 
estáveis. Porém, o seu desenvolvimento tem sido dificultado pela citotoxicidade de alguns 
componentes virais, nomeadamente a protease.  
Neste trabalho de Mestrado, uma protease geneticamente modificada e menos tóxica foi 
avaliada para produção de vetores lentivirais. Embora menos citotóxica, esta protease é menos 
ativa. Enquanto para glicoproteínas do invólucro que não requerem processamento proteolítico 
– VSV-G – a menor atividade da protease não afetou o título do vetor, a conjugação desta 
protease com glicoproteínas utilizadas tipicamente no desenvolvimento de células produtoras 
estáveis – 4070A, GaLV10A1 e RD114A – resultou num título menor. Assim, foi alterado o local 
de clivagem da protease nestas glicoproteínas por meio de engenharia genética. A modificação 
dos locais de clivagem da protease no GaLV10A1 permitiu recuperar os títulos virais para níveis 
semelhantes aos obtidos com a protease wild-type, em produção transiente, com um aumento 
de 5,5 a 36,7 vezes. As glicoproteínas modificadas estão, de momento, a ser implementadas em 
linhas celulares produtoras estáveis, que expressam a protease modificada. 
Este trabalho contribui para o desenvolvimento de uma nova linha celular 
“empacotadora” estável para a produção contínua de vetores lentivirais, descrevendo 
primeiramente o uso da protease modificada e fornecendo novas glicoproteínas quiméricas, 
nomeadamente GaLV10A1giflet. Além disso, esta tese abriu a porta para o uso de uma nova 
glicoproteína modificada com maior título – GaLV10A1ΔR – para o desenvolvimento de linhas 
celulares produtoras estáveis recorrendo à estratégia de knock out do recetor celular de 
GaLV10A1. 
    
 
 
 
  
 
 
Termos chave: Vectores lentivirais; Protease de HIV-1 modificada; Engenharia de glicoproteínas 
do invólucro; Linhas celulares “empacotadoras”. 
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1. Introduction 
 
1.1. Therapeutic potential of viral vectors for gene therapy 
Gene therapy, the treatment or prevention of a disease by genetic material transfer into 
an individual’s cells or tissues, is considered a revolution in the field of medicine, applicable to a 
wide range of diseases, including cancer, monogenic, infectious and cardiovascular diseases1–3 
(Figure 1.1A). The increasing incidence of several unmet medical needs and chronic diseases 
across the world has made gene therapy an attractive market with high growth. According to a 
new report by Visiongain, gene therapy market will achieve revenues of 204 million dollars in 
2020, with the potential to expand to 2026 as new genetic treatments reach the market 4. 
Currently, most of gene therapy products are in clinical development, although some are already 
under commercialization 5. 
 
 
 
 
 
 
 
 
 
Figure 1.1 – Gene therapy clinical trials. (Source: The Journal of Gene Medicine2) A) Diseases 
addressed by gene therapy clinical trials. B) Vectors used in gene therapy clinical trials. 
 
The first gene therapy clinical trial was initiated in 1990, for the treatment of severe 
combined immunodeficiency (SCID). Nowadays, more than 2300 clinical trials have been 
conducted or are still ongoing 2. From these, viral vectors represent more than 70% of gene 
delivery vehicles, with vectors based on Adenovirus, Vaccinia virus, Herpes simplex virus, Adeno-
associated virus, Retrovirus and Lentivirus being the mostly used 2,6 (Figure 1.1B). Each of these 
viral vectors is characterized by a set of different properties that make then suitable for specific 
applications 7. 
Adenoviruses have shown a real promise for cancer therapy and have been the most 
widely used viral vector for gene therapy clinical trials 2. However, their use is decreasing. The 
major drawback of these viruses is their high immunogenicity, proven to be potentially lethal 8. In 
Adenovirus (21.7%) 
Retrovirus (18.3%) 
Naked/Plasmid DNA (17.4%) 
Vaccinia virus (7%) 
Adeno-associated virus (6.7%) 
Lentivirus (5.6%) 
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Infectious diseases (7.6%) 
Cardiovascular diseases (7.5%) 
Neurological diseases (1.8%) 
Ocular diseases (1.4%) 
Inflammatory diseases (0.6%) 
Other diseases (2.3%) 
Gene marking (2.1%) 
Healthy volunteers (2.2%) 
A) B) 
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2003, an Adenovirus based vector for the treatment of head and neck squamous cell carcinoma 
– Gendicine® – was the first gene therapy product released to the market, after approval by the 
China Food and Drug Administration (FDA) 9. Two years later, the China FDA granted market 
approval to another Adenovirus based vector – Oncorine™ – for the treatment of late-stage 
refractory nasopharyngeal cancer in combination with chemotherapy 3. 
Vaccinia viruses have been mostly used for the treatment of cancer and vaccination, 
because of their intense short-lasting transgene expression and cytolytic nature 6. They were 
firstly used in 1995 as an immunotherapy for cervical cancer 10, and they have been used to 
immunize against infectious diseases 2,11. The main disadvantages of Vaccinia virus based 
vectors are the potential cytotoxicity and high immunogenicity. 
Herpes simplex viruses are an interesting gene delivery vehicle due the high infectivity, 
ability to transduce and persist in a latent state in both dividing and non-dividing cells 6. These 
vectors accommodate the largest gene cargos among the viral vectors (up to 50 kb heterologous 
DNA). Since Herpes simplex viruses are neurotropic, they have been successfully used against 
neurological disorders, although cancer therapy is the predominant application in clinical trials 2. 
Yet, 70 to 80% of the population of low socioeconomic status and 40 to 60% from improved 
socioeconomic status carries latent Herpes simplex virus infection 12, exhibiting a specific immune 
response that can efficiently inactivate vector particles and eliminate transduced cells with 
exposed viral proteins. Another safety concern is the reversion of replication deficiency by 
homologous recombination between the Herpes simplex virus based vector and the wild-type 
(WT) genome present in latently infected cells 6. In 2015, the first oncolytic virus in the Western 
world, a Herpes simplex virus based vector for advanced melanoma treatment – Imlygic® – was 
approved for use by the USA FDA and recommended for marketing approval in Europe 13. 
Adeno-associated virus were firstly used in clinical trials for treatment of cystic fibrosis in 
1994 14. Their ability to efficiently transduce a wide variety of dividing and non-dividing cells 
extended their applications to hemophilia, ocular diseases, Alzheimer’s and Parkinson’s disease, 
muscular dystrophies, cardiac failure, dyslipidemia and cancer 15. Their main drawback is the 
small genetic payload they can accommodate (up to 5 kb). Yet, Adeno-associated virus based 
vectors have been experiencing the highest growth rates in gene therapy clinical trials 2, and will 
likely take an important segment of the market in the next years. Glybera®, a recombinant Adeno-
associated virus based vector for the treatment of lipoprotein lipase (LDL) deficiency, was the first 
gene therapy product being commercialized in the European market, after approval in 2012 by 
the European Medicines Agency (EMA) 16.  
Gammaretroviruses, commonly known as retroviral vectors, were the first class of viral 
vectors to be developed and are still one of the most used. Together with their complex 
counterparts, Lentiviruses, Gammaretroviruses are currently the blockbuster vectors for the 
treatment of monogenic, infectious diseases and gene marking clinical trials 2,17. The most 
attractive features of these vectors are the minimal immune response, capacity for a large genetic 
payload (up to 9 kb), and their ability to permanently integrate into a target cell genome, sustaining 
a long-term transgene expression 18. However, Gammaretroviruses transduction is limited to 
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dividing cells. Additionally, there is a risk of insertional mutagenesis and oncogenesis associated 
with the therapeutic use of these vectors 7,19. This year EMA granted market approval to the 
second gene therapy product in the European market – Strimvelis™ – a retroviral vector for the 
treatment of SCID 20. 
In contrast to Gammaretroviruses, Lentiviruses have a distinctive ability to integrate into 
the genome of non-dividing cells 21 and their integration pattern is considered to be safer, with a 
less risk of insertional mutagenesis 22. Therefore, lentiviral vectors (LV) overcome several 
problems of retroviral vectors, resulting in improved biosafety and performance. Together with 
Adeno-associated virus based vectors, LV are the viral vector experiencing the highest growth 
rate in clinical trials 2 and are expected to take over retroviral vectors in gene therapy in years to 
come.  
 
1.2.  Biology of Lentiviruses 
Lentiviruses are human and animal pathogens that are characterized by long incubation 
periods and persistent infection 23. These viruses have garnered attention from both scientists 
and public since 1981, when the first cases of the new epidemic of acquired immunodeficiency 
syndrome (AIDS) were observed 24,25. Later, Human immunodeficiency virus 1 (HIV-1) was 
isolated and identified as the cause of AIDS 26,27. Since then, the biology of HIV-1 has been 
intensively studied. Today it is one of the best understood viruses. 
Lentiviruses are classified as one of the seven genus of the family Retroviridae, 
composed by nine virus species, which includes HIV-1, HIV-2, Simian immunodeficiency virus 
(SIV) and Feline immunodeficiency virus (FIV) 28. All Retroviruses share similarities in structure, 
composition and replicative properties 29. These enveloped viruses harboring a genome of two 
copies of linear positive-sense single stranded RNA with the size of 7-13 kb are mainly 
characterized by an unique replicative strategy – reverse transcription – where the viral RNA is 
reverse transcribed into double stranded DNA, followed by stable integration into the host genome 
29,30. Based on the genome structure, Retroviruses are classified as simple or complex. 
Lentiviruses are included in the complex Retroviruses, with a more complex genome and 
additional regulation steps in their life cycle.  
Lentiviruses virions measure 100 to 120 nm in diameter and the genomic RNA is 
associated with the nucleocapsid protein (NC), enclosed within a protein core composed by 
capsid protein (CA) containing enzymes required for viral infection, such as integrase (IN), 
protease (PR), reverse transcriptase (RT) and accessory proteins (Figure 1.2A). The matrix 
protein (MA) forms a spherical shell outside the core, which in turn is surrounded by the lipid 
bilayer of the virion envelope derived from the host cellular membrane. This lipid bilayer contains 
the viral envelope glycoproteins (Env) responsible for recognizing specific cell surface receptors 
on the host cell, allowing virus entry. Env is formed by the surface (SU) subunit which binds to 
the cell surface receptors and the transmembrane (TM) subunit present as a protein anchor into 
the lipid membrane 30. 
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Figure 1.2 – HIV-1 structure and genome. A) Schematic representation of HIV-1 particle structure. 
Adapted from US National Institute of Allergy and Infectious Diseases. 
http://web.archive.org/web/20050531012945/http://www.niaid.nih.gov/factsheets/howhiv.htm (Accessed: 5th 
August 2016). B) HIV-1 genome and encoded proteins. Green, orange and blue boxes refer to structural, 
accessory or regulatory genes, respectively. Cis-acting components are indicated in grey. Translation 
products are indicated with black arrows. Red arrow represents polyprotein processing by the viral protease. 
Adapted from 31. HIV-1: Human immunodeficiency virus 1; LTR: long terminal repeat; TAR: trans-activator 
response element; ψ: packaging signal; PPT: polypurine tract; cPPT: central polypurine tract; RRE: Rev 
Responsive Element; MA: matrix protein; CA: capsid protein; NC: nucleoprotein; PR: protease; RT: reverse 
transcriptase; Env: envelope glycoprotein; SU: surface subunit; TM: transmembrane subunit. 
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HIV-1 genome has about 9-10 kb and is constituted by several non-coding sequences 
that control gene expression and protein synthesis, and nine genes that code for regulatory and 
accessory proteins in addition to the structural and enzymatic proteins shared among all 
Retroviruses 32 (Figure 1.2B). 
The gag gene encodes a 55 kD polyprotein (Gag) that is cleaved by the viral protease, 
during and after the release of the progeny virions, into the main structural proteins MA, CA and 
NC. The gag-pol sequence encodes a 160 kD polyprotein (Gag-Pro-Pol), resulting from a 
ribosomal frameshift event, that after cleavage by the viral protease during the virus maturation 
gives rise to PR, RT and IN enzymes. These enzymes are responsible for proteolytic cleavage of 
most viral polyproteins, reverse transcription of the viral RNA into DNA and integration of viral 
DNA into the host genome, respectively. The env gene encodes an Env precursor (gp160), that 
is cleaved by cellular proteases into the SU and TM subunits (gp120 and gp41, respectively) 31,33. 
The remaining six HIV-1 genes encode proteins not found in simple Retroviruses. Two of 
these genes encode regulatory proteins Tat (trans-activating regulatory protein) and Rev 
(regulator of expression of viral proteins). Tat increases the transcription of the HIV-1 genome 
several hundredfold by forming a complex with transcriptional factors that interacts with RNA 
polymerase II, increasing its processivity 34. Rev mediates the nuclear export of unspliced or singly 
unspliced mRNA, by multimerizing along the Rev Responsive Element (RRE), and binding to 
cellular factors. The function of Rev is crucial for viral replication, to overcome the cell’s default 
splicing mechanism, necessary for full-length mRNA transcripts of the genome to be packaged 
into progeny virions and for the proper translation of gag-pol and some HIV-1 accessory proteins 
35. 
The final four genes encode accessory proteins: Vif, Nef, Vpr and Vpu. These proteins 
are not crucial for viral replication in vitro, but all play one or more roles in disease progression or 
pathogenesis in man 31. 
The HIV-1 genome contains non-coding cis-acting sequences that play important roles in 
viral replication 29. The long terminal repeat (LTR) is a regulatory sequence of DNA found at both 
the 5’ and 3’ ends of the provirus which contain elements required to drive gene expression, 
reverse transcription and integration into the host cell genome. In the 5’ LTR there is the trans-
activator response element (TAR) that interacts with the complex formed by Tat and 
transcriptional factors. In addition to the polypurine tract (PPT) at the beginning of the 3’LTR, 
lentiviruses have an additional central PPT (cPPT), both of which are used for positive strand 
DNA synthesis during reverse transcription 31. The packaging signal (ψ) allows specific packaging 
of the viral genomic RNA into progeny virions 36. RRE is a structured RNA element within the env 
gene, recognized by Rev.  
The life cycle of HIV-1 is illustrated in Figure 1.3. The main difference between the simple 
Retroviruses (like Gammaretroviruses) and Lentiviruses is the capacity of the latter to integrate 
their genomes into the nuclear DNA without requiring cell division 29. Therefore, lentiviral vectors 
transduce dividing and non-dividing cells, oppositely to retroviral vectors that only transduce the 
first ones, making lentiviral vectors a better choice for gene therapy. For gene therapy 
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applications, the ideal viral vectors harness the infection pathway without leading to their 
replication and toxicity 7. This assumes the use of packaging systems with a split genome 
approach for replicative deficient lentiviral vector production. 
 
 
Figure 1.3 – Schematic overview of the HIV-1 replication cycle. The figure illustrates the main 
steps in the HIV-1 replication cycle. HIV-1 infection begins with virion binding to the CD4 receptor and co-
receptors. Viral entry occurs by fusion of the viral membrane with the host cell membrane. Uncoating of the 
viral capsid takes place and HIV-1 RNA is reverse transcripted into DNA. The pre-integration complex (PIC) 
is formed and double-stranded DNA product is translocated into the nucleus and integrated into the 
chromosomal DNA by the integrase, creating the provirus. The integrated viral DNA is subsequently 
transcribed and translated to form new viral RNA and viral proteins. Viral components are transported to the 
cell surface to assemble into virus particles. The progeny virus particles bud off and are released. During 
maturation, proteolysis by the viral protease generates infectious virions. HIV-1: Human immunodeficiency 
virus 1; PIC: pre-integration complex; LTR: long terminal repeat. Adapted from 37. 
 
1.3.  Design of lentiviral vector packaging systems 
The use of a highly pathogenic human virus in gene therapy applications raises series 
biosafety concerns. Therefore, the design of packaging systems has evolved in order to increment 
the efficiency and the safety of lentiviral vector while minimizing the possibility of replication-
competent lentiviruses (RCL) during vector production 38,39. Currently, four generations of lentiviral 
vectors are considered. 
The first generation, developed by Naldini and co-workers, consisted in a three 
expression cassettes system 21. The packaging cassette had all structural, accessory and 
regulatory proteins, with the exception of the envelope glycoprotein. The transgene cassette was 
composed by the 5’LTR, the packaging signal, the RRE cis-acting region and the transgene under 
the control of a heterologous promoter. In the envelope glycoprotein expression cassette, the 
native HIV-1 envelope glycoprotein was replaced by the vesicular stomatitis virus G glycoprotein 
(VSV-G). With this system, good titers were easily achieved, but the poor safety level could not 
be accepted for a human and potentially lethal pathogen. RCL could be generated with three 
homologous recombination events between the viral sequences of the packaging and transgene 
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cassette or endogenous retroviral sequences within the producer cells. Additionally, the presence 
of the LTR promoter could activate neighboring cellular genes, and the presence of all accessory 
HIV-1 genes, which are incorporated into the viral particle, enhanced the immunogenicity of the 
vector 38. 
In the second generation 40, all accessory genes were deleted from the three plasmid 
system, without negative effects on vector titer. By removing the accessory genes (vpr, vif, vpu 
and nef), the generation of RCL became less probable and, if generated, would be unlikely to be 
pathogenic 32. 
The third and still most widely used generation was developed by Dull and co-workers 41 
(Figure 1.4). It is characterized by the deletion of the tat gene from the packaging plasmid and 
rev gene placed in an independent plasmid. The tat sequence was replaced by a chimeric 5’LTR 
with a heterologous viral promoter/enhancer, such as those of Cytomegalovirus (CMV) or Rous 
sarcoma virus (RSV). Therefore, lentiviral vector expression is independent of Tat. Rev is 
maintained but is provided by an independent non-overlapping plasmid. Thus, this system has a 
total of four constructs, increasing the number of homologous recombination events required for 
RCL formation. Another feature of this generation is the partial deletion of the 3’LTR in the 
transgene cassette, leading to transcriptional inactivation of the LTR promoter, after reverse 
transcription. These vectors are called self-inactivating (SIN) vectors. This inactivation increases 
safety and reduces concerns related to insertional mutagenesis in the neighboring sequences 
that can lead to the transactivation or up-regulation of neighboring genome sequences, such as 
oncogenes 39. 
 
 
 
 
 
Figure 1.4 – Third generation lentiviral vector packaging system 41. From top to bottom: 
packaging cassette, rev independent cassette, transgene cassette, envelope glycoprotein (usually VSV-G) 
cassette. 
 
A fourth generation of lentiviral vectors, Rev independent, has also been developed by 
means of replacing RRE with heterologous viral sequences or by codon-optimization 17. These 
packaging systems are not, however, easily available for the research community. Also, the 
reported titers are one to two logs lower than that of the second or third generation systems. 
 
1.4.  Pseudotyping lentiviral vectors 
The envelope glycoprotein defines the tropism of the virus by interacting with specific cell 
surface proteins and promoting the entrance of viruses into the host cell. The natural tropism of 
env polyA Promoter 
rev polyA Promoter 
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LTR Transgene 
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gag-pol Promoter polyA RRE 
8 
 
HIV-1 envelope glycoprotein is restricted to CD4+ cells, thus limiting its gene therapy applications 
to CD4+ cells like macrophages or T cells 42. However, lentiviral vectors have the ability to 
incorporate in their viral particles envelope glycoproteins from other viruses. This feature, 
denominated pseudotyping, allows the manipulation of vector tropism 32,38. 
The most used pseudotyping envelope glycoprotein in lentiviral vectors is VSV-G, due to 
its wide tropism (possibly pantropism), with high titers achieved and improved vector stability, 
allowing the concentration of the particles by ultracentrifugation and resistance to freeze-thaw 
cycles 43. Despite all the advantages, VSV-G is toxic to producer cells, posing a challenge to 
stable production of lentiviral vectors pseudotyped with this envelope glycoprotein (discussed 
later). Moreover, the broad tropism of VSV-G can be an impediment for targeted transduction of 
specific tissues, for example, for in vivo applications 43. Another limitation to its use for in vivo 
application is the inactivation of VSV-G by human complement present in the blood 44. 
Several alternative envelope glycoproteins have been studied and are also suitable for 
pseudotyping lentiviral vectors, for example, the amphotropic Murine leukemia virus (MLV) 4070A 
envelope glycoprotein which is able to transduce most cells 32. Other envelope glycoproteins have 
been engineered to pseudotype lentiviral vectors with increased efficiency, for example the 
chimeric envelope glycoproteins RD114A 45,46 and RDpro 47,48 derived from the endogenous 
Feline leukemia virus (RD114) and GaLV10A149 derived from the Gibbon ape leukemia virus 
(GaLV). 
Despite specific advantages and disadvantages, each envelope glycoprotein confers a 
different set of properties to the lentiviral vector, and so each pseudotype may have its own 
potential niche 43,50. 
 
1.5. Production of lentiviral vectors 
For research and clinical purposes, Human Embryonic Kidney (HEK) 293 and its derivate 
HEK 293T cell lines have been the most used cell substrates for large scale production of lentiviral 
vectors 51. HEK 293T cells, due the presence of the Simian virus 40 (SV40) large T antigen, are 
preferable because they show superior growth, transfection efficiency and vector productivity in 
comparison to HEK 293 cells 52. For research purposes, other human or monkey derived cells 
have been used (other 293 derived clones, HeLa, HT1080, TE671, COS-1, COS-7, CV-1), 
although most of them showed reduced vector production titers 52. 
Lentiviral vectors can be produced by transient transfection or stable producer cell lines 
(Figure 1.5). 
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Figure 1.5 – Transient transfection and stable production of lentiviral vectors. A) Transient 
production after transfection of plasmids from third generation lentiviral vector packaging system into HEK 
293T cells. B) Stable production from packaging cell lines that constitutively express the viral components. 
 
In transient transfection production, cells are co-transfected with the viral constructs 
(Figure 1.5A). Between 24 to 72 hours post-transfection, the lentiviral vectors present in the 
supernatant are harvested.  
Stable production relies on packaging cell lines (PCLs) in which all of the components 
necessary to produce vectors are integrated into the cells’ genome (Figure 1.5B). To establish a 
PCL for stable production, the packaging, envelope and transgene constructs are inserted one-
by-one, followed by clonal selection in between insertions, making the development of stable cell 
lines a tedious and long lasting process that can take up to one year for a fully developed and 
characterized cell platform 17. Most LV batches, including those used in clinical trials to date, have 
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been produced by transient transfection of HEK 293T cells with multiple plasmids. Transient 
transfection production is faster compared to the time frame necessary to develop a stable 
packaging cell line, presenting very competitive titers (up to 107 infectious vectors per milliliter). 
Yet, for large-scale production means, transient systems are cumbersome since are difficult to 
standardize, scale-up, time and cost-ineffective and exhibit high batch-to-batch variability 17,52. 
Stable producer cell lines will facilitate the transition from clinical to market, because of the easy 
scalability, increased safety and well characterized production process 51.  
The establishment of a stable packaging cell line for lentiviral vector production has been 
hampered by the cytotoxicity of viral proteins like Tat, Nef, Vpr and protease 53. From these, only 
the protease is still required in the current packaging systems. HIV-1 protease mediates its 
cytotoxicity in vitro and in vivo by cleaving and activating procaspase 8, leading to mitochondrial 
release of cytochrome c, activation of the downstream caspases 9 and 3 and nuclear 
fragmentation 54,55. Due to the cytotoxic and cytostatic effects of HIV-1 gag-pol genes, high 
expression of these genes in packaging cell lines has also been challenging. Additionally, the 
most widely utilized envelope glycoprotein for lentiviral vectors, VSV-G, is highly cytotoxic 56. 
At small-scale and for research purposes, transient production by plasmid transfection 
has been the first choice to cope with the cytotoxic proteins 17. For large-scale production 
purposes, conditional packaging systems have been developed in which the expression of toxic 
proteins are controlled by inducible systems 52. The first and more frequently used inducible 
systems are based on the well-defined and characterized tetracycline-inducible expression 
system 57. In the Tet-on and Tet-off systems, addition or removal, respectively, of the 
tetracycline/doxycycline antibiotic in the culture medium triggers gene transcription. At the 
beginning, the titers obtained using conditional packaging cell lines were low, but further 
improvements led to similar levels compared to transient production titers 52. As it happens in 
transient transfection production, these systems can only produce lentiviral vectors for a few days 
after induction due to the cytotoxicity of induced viral components. Also, additional purification 
steps of the viral preparations are required to eliminate inducing agents, hindering the scaling-up 
of conditional systems for clinical-grade lentiviral vectors production 17. In addition, packaging 
cells have often been shown to be instable due to leaky expression of the toxic proteins 51.  
Constitutive packaging cell lines are a preferable production system. These cells however 
are more difficult to obtained than inducible cells, due to the previously discussed cytotoxicity of 
some viral components. The unfeasible use of VSV-G and the selection of highly gag-pol 
expressing cells seem to be the main challenges 52. Until the date, four constitutive packaging cell 
lines have been reported (Table 1.1). 
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Table 1.1 – Constitutive packaging cell lines for lentiviral vector production. 
Packaging cell line 
LV 
generation 
Envelope 
glycoprotein 
Titer 
(T.U./ml) 
Delivery of viral 
components 
STAR 47 Second 
RDpro 
GaLV10A1 
MLV 4070A 
8.5 x 106 
1.6 x 106 
1.2 x 107 
Codon-optimized gag-
pol inserted by MLV 
vector transduction 
WinPac 58 Third RDpro 1 x 106 
MLV vector transduction 
combined with RMCE 
technology 
RD2-MolPack-Chim3 59 Second 
RD114A 1 x 107 
Integrating vectors 
(chimeric baculo-AAV 
and LV) RD3-MolPack-GFP 60 Third 
T.U.: Transduction units; LV: Lentiviral vectors; MLV: Murine Leukemia Virus; AAV: Adeno-
associated virus vector; RMCE: recombinase-mediated cassette exchange. 
 
Ikeda and co-workers developed, in 2003, the first continuous packaging cell line, STAR 
47, producing second generation lentiviral vectors for up to three months in culture with a titer of 
107 TU/ml. They used a strategy of codon optimization of HIV-1 gag-pol and the envelope 
glycoprotein derived from the RD114 with the R-peptide cleavage site replaced with that of the 
HIV-1 matrix/capsid (MA/CA) in Gag (RDpro) 47. Later, they tested the chimeric envelope 
glycoproteins derived from GaLV with an MLV 10A1 cytoplasmic tail (GaLV10A1) and the 4070A, 
demonstrating that VSV-G can be replaced by others envelope glycoproteins to avoid its 
cytotoxicity 61. However, significant titers could only be obtained after MLV vector transduction of 
the optimized gag-pol. This procedure raises biosafety issues, due to the increasing chance of 
generating RCL by homologous recombination, posing further concerns of co-packaging 39. This 
risk was later reduced in the development of the WinPac cells 58, by using the MLV vector 
transduction combined with the recombinase-mediated cassette exchange (RMCE) technology 
62. WinPac cells with the RDpro can continuously produce third generation lentiviral vectors at 
titers in the order of 106 TU/ml 58. 
Another constitutive packaging technology, RD-MolPack cells 59,60, were developed by 
MolMed S.p.A, Milan. Unlike STAR and WinPac cells, the envelope glycoprotein used in this 
packaging system is a chimeric RD114 envelope glycoprotein with the 4070A cytoplasmic tail 
(RD114A). RD-MolPack technology is characterized by the sequential insertion of the viral genes 
by integrating vectors. Packaging genes were introduced by infecting 293T cells with a chimeric 
baculo-AAV vector. The remaining components were delivered by LV transduction. Similarly to 
STAR cells, the use of MLV or lentiviral vectors in the construction of packaging cell lines raises 
biosafety issues 39. RD2-MolPack and RD3-MolPack cells produce second and third generation 
lentiviral vectors, respectively, at titers in the order of 107 TU/ml 59,60. 
As observed in the reported constitute packaging cell lines, non-toxic Gammaretroviruses 
envelope glycoproteins can be used to pseudotype lentiviral vectors to overcome the significant 
issue of VSV-G. However, the cytotoxicity induced by the HIV-1 protease is still to be addressed. 
Additionally, the described constitutive packaging cell lines are shown to be unstable and 
exhibited an abnormal morphology. In our lab we have observed this with STAR cells. 
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1.6.  Aim and strategy 
The aim of this work was to provide new tools for the development of a novel lentiviral 
vector packaging cell line for the constitutive production of these vectors. In this context, we 
generated a point mutation in the active site of the HIV-1 protease. This mutation consisted in 
changing amino acid 26 from a threonine to a serine (T26S). According to Konvalinka and co-
workers, this mutation led to a 5- to 10-fold decrease in the protease activity compared to the WT 
HIV-1 protease and, consequently, to a reduced cytotoxicity without effect on virus maturation 
and infectivity 63. Yet, the authors did not report the use of T26S HIV-1 protease for lentiviral 
vector production. Thus, in this work we aimed to minimize cytotoxicity induced by the viral 
protease in lentiviral vector production by using the less toxic T26S HIV-1 protease. 
The first objective consisted on the validation of T26S HIV-1 protease for lentiviral vector 
production. To accomplish this, proteolytic processing of Gag-Pro-Pol and Gag polyproteins by 
the protease was assessed and transient transfection production with third generation lentiviral 
vector packaging was performed. Additionally, we have tried to elucidate the cytotoxicity mediated 
by the HIV-1 protease using an inducible system. 
Since the commonly used envelope glycoprotein VSV-G cannot be used to establish a 
packaging cell line for stable and constitutive production of lentiviral vectors, we evaluated 
lentiviral vector production with non-cytotoxic Gammaretroviruses envelope glycoproteins, using 
4070A, RD114A 45,46 and GaLV10A1 49. In order to enhance viral titers conjugated with T26S HIV-
1 protease, the cleavage site of the HIV-1 protease in the TM subunit was engineered. 
After evaluation of lentiviral vector production using T26S HIV-1 protease and engineered 
envelope glycoproteins, these components will be used to establish a stable producer cell line 
and viral titers will be assessed (the establishment of the stable producer cell line was already 
started in this thesis). 
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2. Materials and Methods 
 
2.1.  Plasmids 
Primers and templates for all the plasmids constructed in this work are listed in Table A.1 
in annexes. A schematic representation of the constructed plasmids main transcriptional units is 
provided in Figure A.1 in annexes. 
pMDLg/pRRE is a third generation lentiviral vector packaging plasmid expressing HIV-1 
gag-pol under the control of a CMV promoter, and RRE, a binding site for the Rev protein which 
facilitates export of the RNA from the nucleus. pRSV-Rev is a third generation lentiviral vector 
packaging plasmid containing the second and third exons of HIV-1 rev under the control of RSV 
U3 promoter. These plasmids were kindly provided by Dr. Didier Trono through Addgene plasmid 
repository (Cambridge, MA, USA) (plasmids # 12251 and # 12253, respectively) and are 
described in 41. 
pRRLSIN-CMV-GFP is a third generation lentiviral transgene plasmid, driving the 
expression of enhanced green fluorescent protein (eGFP) from the CMV promoter. This plasmid 
is an in-house constructed plasmid, derived from pRRLSIN.cPPT.PGK-GFP.WPRE, kindly 
provided by Dr. Didier Trono through Addgene plasmid repository (plasmid # 12252) where the 
human phosphoglycerate kinase 1 (PGK) promoter was replaced by the CMV promoter. 
pMDLg/pRRET26S and pMDLg/pRRED25N are in-house constructed plasmids derived from 
pMDLg/pRRE, with the mutations T26S and D25N in the HIV-1 protease active site, respectively. 
The T26S mutation is described to cause reduced proteolytic activity and loss of protease-
mediated cytotoxicity 63; the D25N mutation inactivates the active site of the protease 64. 
All previously described plasmids were used to produce lentiviral vector by transient 
transfection as reported in 41, pseudotyped with different envelope glycoproteins. 
pMD2.G encodes VSV-G under the control of the CMV promoter. This plasmid was kindly 
provided by Dr. Didier Trono through Addgene plasmid repository (plasmid # 12259). 
phGaLV10A1 encodes GaLV10A1 and zeocin resistance marker under the transcriptional 
control of the CMV promoter and contains rabbit beta-globin (RBG) and hemoglobin subunit beta-
2 (HBB2) introns upstream the start codon. GaLV10A1 is a modified GaLV envelope glycoprotein 
with the substitution of the cytoplasmic tail by that of the MLV clone 10A1 49. This plasmid was 
kindly provided by Dr. Otto Merten (Généthon, Évry, France). 
pCMV-GaLV10A1 was constructed by removing a 19 nucleotides sequence prior to the 
start codon of galv10a1 from phGaLV10A1 by inverse PCR.  
pCMV-4070A and pCMV-RD114A encode envelope glycoprotein 4070A of the 
amphotropic MLV and a modified RD114 envelope glycoprotein, RD114A45,46, with the 
substitution of the cytoplasmic tail by that of the 4070A, respectively. pCMV-4070A and pCMV-
RD114A were derived from phGaLV10A1 in which galv10a1 was removed by EcoRI and KasI 
restriction and replaced by 4070a and rd114a, respectively. 4070a and rd114a were amplified by 
PCR from pMonoZeo-4070A (in-house constructed plasmid, described in 65) and pLTR-RD114A, 
14 
 
kindly provided by Jakob Reiser through Addgene plasmid repository (plasmid # 17576, described 
in 46). 
pCMV-4070AΔR, pCMV-GaLV10A1ΔR and pCMV-RD114AΔR encode 4070A, GaLV10A1 
and RD114A, respectively, with the deletion of the R-peptide from the cytoplasmic tail. Each 
plasmid was amplified by inverse PCR from the parental plasmids previously described, to 
remove the nucleotides coding for the R-peptide of the cytoplasmic tail of the envelope 
glycoprotein genes. 
pCMV-4070Apro, pCMV-GaLV10A1pro and pCMV-RD114Apro encode 4070A, GaLV10A1 
and RD114A, respectively, in which the R-peptide cleavage site sequence was replaced by that 
of the HIV-1 matrix/capsid (MA/CA) in HIV-1 Gag. Each plasmid was amplified by inverse PCR 
from the parental plasmids to substitute the natural R-peptide cleavage site sequence – 
VQAL↓VLTQ (amino acid sequence) – with the cleavage site of MA/CA – SQNY↓PIVQ. 
pCMV-4070Agiflet, pCMV-GaLV10A1giflet and pCMV-RD114Agiflet encode 4070A, 
GaLV10A1 and RD114A, respectively, with a synthetic R-peptide cleavage site sequence 
reported as the most efficiently cleaved peptide site – GSGIF↓LETSL 66 – by the HIV-1 protease. 
The construction of these plasmids was conducted in two steps to replace the natural R-peptide 
cleavage site sequence with the synthetic sequence. In the first step, each plasmid was amplified 
by inverse PCR from the parental plasmids to substitute the sequence VLTQ of the natural R-
peptide cleavage site with the LETSL. In the second step, the same approach was used to replace 
the VQAL sequence with the GSGIF sequence.  
pTet-GFP/PGK-Zeo encodes eGFP under the transcriptional regulation of a bidirectional 
Tet-dependent (BiTet) promoter and a zeocin resistance marker from the PGK promoter. The 
backbone was derived from phGaLV10A1, where galv10a1 was removed by inverse PCR and 
replaced by egfp amplified from pRRLSIN.cPPT.PGK-GFP.WPRE by PCR. The PGK promoter 
was amplified by PCR from pRRLSIN.cPPT.PGK-GFP.WPRE and inserted 20 nucleotides 
upstream of the zeocin resistance marker. The BiTet promoter was isolated from pTargLox-
polyATetVSV-G-FerHprom (in-house constructed plasmid) by BamHI restriction to replace the 
CMV-RBG-HBB2 sequence removed by inverse PCR. 
pTet-HIV1 PRWT/PGK-Zeo, pTet-HIV1 PRT26S/PGK-Zeo and pTet-HIV1 PRD25N/PGK-Zeo 
expresses the WT, T26S and D25N HIV-1 proteases under the control of the BiTet promoter, 
respectively. The coding sequences for the proteases were amplified from the respective 
pMDLg/pRRE plasmids by PCR and replaced egfp in pTet-GFP/PGK-Zeo (removed by EcoRI 
restriction). These plasmids were used to develop stable cell lines with inducible expression of 
HIV-1 proteases. 
pRRLSIN-mCherry-hPGK-GFP is a lentiviral transgene plasmid, driving the expression 
of mCherry protein from the LTR promoter and eGFP from the LTR and PGK promoters. This 
plasmid was constructed by Hélio Tomás (ACT Unit IBET/ITQB NOVA, Oeiras, Portugal), and 
was used to establish stable cell lines for lentiviral vector production. 
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2.2.  Cloning procedure 
All PCR reactions were performed with Phusion® High-Fidelity DNA Polymerase 
(Finnzymes Oy, Vantaa, Finland), using the conditions suggested by the manufacturer. The 
restriction enzymes (New England Biolabs, Ipswich, MA, USA) were used with the appropriate 
buffer according to the manufacturer’s instructions. Generated fragments by restriction or PCR 
reactions were isolated by 0.7% (w/v) agarose gels (NZYTech, Lisbon, Portugal), and purified 
with NucleoSpin® Gel and PCR Clean-up Kit (Macherey-Nagel, Düren, Germany). Cloning 
reactions were performed using In-Fusion® HD Cloning Kit (Clontech Laboratories, Inc., Mountain 
View, CA, USA) following manufacturer’s instructions. 
 
2.3.  Bacterial strains and culture media 
 Escherichia coli (E. coli) Stellar™ (Clontech Laboratories, Inc.), NZY5α (NZYTech) and 
One Shot® Stbl3™ (Life Technologies, Carlsbad, CA, USA) competent cells were used for the 
production of the plasmids. Transformation procedures were performed under the manufacturer’s 
instructions. 
 The liquid and agar cultures were performed with Terrific Broth (Fast-Media® TB; 
InvivoGen, San Diego, CA, USA) and Luria Broth (Fast Media® LB; InvivoGen), respectively, 
supplemented with the appropriate antibiotic (ampicilin, kanamycin, blasticidin or puromycin). The 
media were prepared using ultrapure water (Milli-Q®, Merck Millipore, Billerica, MA, USA). 
 
2.4.  Plasmid purification and quality control 
Plasmid purification was performed at small-scale purification (yields up to 20 µg of DNA) 
with GeneJET Plasmid Miniprep Kit (Thermo Scientific™, Waltham, MA, USA) and larger scale 
purification (yields up to 500 µg of DNA) with Genopure Plasmid Maxi Kit (Roche Applied Science, 
Penzberg, Germany) following manufacturers’ instruction. Working bacteria banks for each 
plasmid were generated and stored at -20ºC with 15-20% (v/v) glycerol (Sigma-Aldrich, St. Louis, 
MO, USA). 
The DNA concentration was determined using Nanodrop™ 2000C Spectrophotometer 
(Thermo Scientific™). Plasmid purity was assessed by the Abs260nm/Abs280nm and 
Abs260nm/Abs230nm ratios. Plasmid integrity was assessed with 0.7% (w/v) agarose gels (NZYtech). 
All generated plasmids were sequenced using GATC Biotech services (Constance, Germany). 
 
2.5.  Cell lines and culture conditions 
HEK 293T (ATCC CRL-11268), is a Human Embryonic Kidney 293 derived cell line that 
constitutively expresses the SV40 large T antigen. Cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco™, Carlsbad, CA, USA), supplemented with 10% (v/v) Fetal 
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Bovine Serum (FBS) (Gibco™) at 37 °C in a humidified atmosphere containing 8% CO2. All cells 
were cultured under adherent conditions (t-flask) (Starstedt, Nümbrecht, Germany). 
 
2.6.  Determination of cell concentration and viability 
Cell concentration and viability were determined by the trypan blue exclusion assay, using 
a 0.1% (v/v) Trypan Blue (Sigma-Aldrich) solution in Phosphate Buffer Saline (PBS) (Gibco™). 
Cell count was performed in a Fuchs-Rosenthal hemocytometer (Marienfeld-Superior, Lauda-
Königshofen, Germany) on an inverted microscope (Olympus, Tokyo, Japan). 
 
2.7.  Cell transfection procedure 
For transfection procedure, cells were seeded at 5 × 104 cells/cm2. After 24 hours, 
transfection was carried using polyethylenimine (PEI, Linear 25kDa) (Polysciences, Inc., 
Warrington, PA, USA) at 1:1.5 (w/w) ratio of DNA:PEI. A total of 5 µg of plasmid per million of 
cells was used. PEI transfection solution and plasmid mix solution were prepared in serum-free 
DMEM. Plasmid mix solution was filtered through 0.22 µm-pore-size cellulose acetate filter to the 
PEI transfection solution. After 10 to 15 minutes incubation at room temperature, transfection 
solution was added to the cells. 
 
2.8.  Establishment of stable cell lines with inducible HIV-1 protease gene expression 
 To establish stable cell lines with inducible HIV-1 protease gene expression, pTet-HIV1 
PRWT/PGK-Zeo, pTet-HIV1 PRT26S/PGK-Zeo and pTet-HIV1 PRD25N/PGK-Zeo were separately 
transfected into HEK 293T cells as previously described. pTet-GFP/PGK-Zeo was used as 
control. The transfection procedure was performed in a 6-well plate. 48 hours post-transfection, 
cells were transferred into a 25 cm2 t-flask and zeocin selection was started (200 µg/ml; 
InvivoGen). Medium was regularly exchanged during 4 weeks. Complete selection was 
considered when the cells in the t-flask reached confluence after standard splitting dilutions (1:15 
and 1:30) in the following 3 or 4 days (respectively).  
 
2.9.  Growth study and induction conditions 
 Cells with inducible HIV-1 WT, T26S and D25N proteases gene expression were seeded 
at 2 × 104 cells/cm2 in 6-well plates. 12 hours after seeding, gene expression was induced by 1 
µg/ml of doxycycline (Sigma-Aldrich) added every 24 hours. Cells were counted every 10 to 14 
hours during the following 6 days. Protein and RNA extraction was conducted two days after 
induction. 
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2.10. Protein extraction and quantification 
Cells were harvested and pelleted at 300 × g for 10 minutes and washed with cold PBS. 
A total of 2 × 106 cells was used for protein extraction. Two protocols were performed, depending 
on the use of the extracts. For HIV-1 protease activity assay, cells were ressuspended with 100 
µl of hypotonic buffer (10mM Tris-HCl, pH 7.8, 10 mM NaCl) per million of cells and incubated on 
ice for 20 minutes. Cell pellets were disrupted with freeze and thaw cycle (3 times) in liquid 
nitrogen and water bath at 37ºC. For HIV-1 polyprotein processing analysis by western blotting, 
cells were lysed in 100 µl Mammalian Protein Extraction Reagent (M-PER) (Thermo Scientific™) 
per million of cells. cOmplete™ EDTA-free Protease Inhibitor Cocktail (Roche Applied Science) 
was added to M-PER. The mixture was shaken for 10 seconds in the vortex and placed in ice for 
5 minutes. This last step was repeated 2 times. Extracts were clarified by centrifugation at 13500 
× g. Samples were frozen at -20ºC for short-term and -80ºC for long-term storage. Total protein 
quantification was performed with Pierce™ BCA Protein Assay Kit (Thermo Scientific™), 
according to manufacturer’s instructions. 
 
2.11. Western blot analysis of HIV-1 polyprotein processing 
Cells were transfected with pRSV-Rev and pMDLg/pRRE and its variants (WT, T26S and 
D25N), as previously described. A plasmid DNA ratio of 1:3 was used, respectively. 48 hours 
later, protein extracts were performed for HIV-1 polyprotein processing analysis by western 
blotting, as previously described. 
For protein electrophoresis separation, NuPAGE® electrophoresis system (Life 
Technologies) was used. Samples were prepared in denaturing conditions according to 
manufacturer’s instructions. Samples were resolved on a NuPage® 4-12% Bis-Tris gel with 
NuPAGE® MES SDS Running Buffer, at 180 V for 35 minutes. Protein transfer into nitrocellulose 
membrane was performed in Trans-Bot® Turbo™ Transfer System (Bio-Rad, Hercules, CA, USA) 
for 30 minutes, according to manufacturer’s instructions. Membranes were blocked with blocking 
solution 0.1% (w/v) tween 20 (Sigma-Aldrich) and 5% (w/v) skim milk powder (Sigma-Aldrich) in 
Tris-Buffered Saline (TBS) (Sigma-Aldrich), for 30 minutes at room temperature and incubated 
overnight with primary antibody, anti-HIV1 p24 antibody [39/5.4A] (ab9071) (Abcam, Cambridge, 
UK), diluted 1:2000 in blocking solution with gentle agitation. Membranes were washed 3 times 
with washing solution 0.1% (w/v) tween 20 in TBS and incubated with secondary antibody, 
horseradish peroxidase-linked ECL Anti-Mouse IgG (NA931) (GE Healthcare, Little Chalfont, UK) 
diluted 1:5000 in blocking solution for 2 hours at room temperature. Chemiluminescence detection 
was performed by incubating the membranes with Amersham™ ECL™ prime western blotting 
detection reagent (GE Healthcare), according to manufacturer’s instructions, and analyzed under 
ChemiDoc XRS System (Bio-Rad). 
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2.12. Measurement of HIV-1 protease activity 
To measure HIV-1 protease activity in the protein extracts of cells with inducible HIV-1 
WT, T26S and D25N proteases gene expression, the HIV-1 protease activity fluorometric assay 
kit (BioVision, Inc., Milpitas, CA, USA) was used, following the manufacturer’s instructions. 
 
2.13. RNA extraction and real-time quantitative PCR for gene expression 
To assess gene expression of cell surface receptors SLC20A2, SLC1A5 and SLC20A1 
(receptors for 4070A, RD114A and GaLV10A1, respectively) HEK 293T cells were inoculated as 
previously described. 48 hours later, total RNA was extracted using RNeasy Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. RNA yields were quantified using 
Nanodrop 2000C Spectrophotometer. cDNA synthesis was performed using Transcriptor High 
Fidelity cDNA Synthesis Kit (Roche Applied Science) using 2 µg of total RNA and anchored-
oligo(dT)18 primers for total mRNA reverse transcription, according to manufacturer’s instructions. 
The cDNA was aliquoted and stored at -20ºC until further use. For real-time quantitative PCR 
(RT-qPCR), RPL22 was chosen as a control gene. Forward and reverse primer sequences are 
listed in Table A.1 in annexes. RT-qPCR was conducted on a thermocycler LightCycler® 480 
Real-Time PCR System (Roche Applied Science) using LightCycler® 480 SYBR Green I Master 
(Roche Applied Science). Gene expression was quantified after normalization to RPL22 using 2-
ΔCT method. 
 
2.14. Lentiviral vectors production and titration  
2.14.1. Transient production 
For transient production of lentiviral vectors, the third generation lentiviral packaging 
system and the transfection procedure described in 41 were used. The transfection procedure was 
conducted using PEI as previously described. HEK 293T cells were seeded at 5 × 104 cells/cm2 
in 25 cm2 t-flask 24h prior to transfection. A total of 4.65 µg of plasmid DNA per million cells was 
used for the transfection of one t-flask: 1 µg of pMDLg/pRRE or its variants (T26S and D25N) and 
0.25 µg of pRSV-Rev (providing the packaging functions), 2.5 µg of pRRLSIN-CMV-GFP 
(providing the transgene vector) and 0.9 µg of envelope glycoprotein encoding plasmid. After 20 
to 24 hours post transfection, the medium was replaced with 4 ml of DMEM supplemented with 
10% (v/v) FBS. For titration of total particles by nanoparticle tracking analysis, serum-free DMEM 
was used in this step. After an additional production period of 24 hours, the medium containing 
the viral vectors was harvested, filtered through 0.45 µm-pore-size cellulose acetate filter for 
clarification, aliquoted and stored at -80ºC until further use. To assess transfection efficiency, 
transfected cells were harvested and analyzed for GFP fluorescence by flow cytometry (CyFlow® 
Space, Sysmex Corporation, Kōbe, Japan). 
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2.14.2. Titration of infectious particles 
For titration of infectious particles (I.P.), HEK 293T cells were seeded at 5 × 104 cells/cm2 
in 24-well plates 24 hours before infection. Transduction was performed by removing the cell 
supernatant and infecting cells with 0.2 ml of viral supernatants at several dilutions performed in 
DMEM supplemented with 10% (v/v) FBS containing 8 µg/ml of polybrene (Sigma-Aldrich). For 
normal transduction protocol, cells were incubated at 37 ºC overnight after which 0.5 ml of DMEM 
supplemented with 10% (v/v) was added. For spin inoculation protocol, the plates were 
centrifuged at 1200 × g, 25 ºC for 2 hours after which 0.5 ml of fresh supplemented DMEM was 
added and cells were incubated at 37 ºC. Two days after infection, cells were harvested and 
analyzed for GFP fluorescence by flow cytometry (CyFlow® Space). 
The I.P. titer was determined taking into account the percentage of GFP positive cells, 
the number of cells determined at infection time and the dilution factor of the viral supernatant. 
Infections that rendered 2-20% of infected cells were considered for titer calculations. Viral titers, 
defined as infectious particles per milliliter (I.P./ml) were calculated using the following equation: 
 
I. P.
ml
=
%GFP positive cells ×number of cells at infection time×dilution factor
100×infection volume (ml)
 
 
2.14.3. Titration of total particles 
Physical (total) particles (T.P.) in the serum-free viral supernatant were assessed by 
Nanoparticle Tracking Analysis (NTA) using NanoSight® NS500 (Malvern Instruments Ltd, 
Malvern, UK), following the manufacturer’s instructions.  
For viral supernatants containing serum, a p24 enzyme-linked immunosorvent assay 
(ELISA) – INNOTEST HIV Antigen mAb (Fujirebio Diagnostics, Inc., Malvern, PA, USA) – was 
used to quantify total particles, according to the manufacturer’s instructions. 
 
2.15. Establishment of stable cell lines for lentiviral vector production 
HEK 293T cell line constitutively expressing HIV-1 gag-pol with T26S mutation and rev, 
developed by Hélio Tomás (ACT Unit IBET/ITQB NOVA), was used to establish stable cell lines 
for lentiviral vector production with T26S HIV-1 protease and engineered envelope glycoproteins. 
Blasticidin (15 µg/ml, InvivoGen) and hygromicin B (150 µg/ml, InvivoGen) were the antibiotics 
used for the selection of clones expressing gag-pol and rev, respectively. Cells were transfected 
with pRRLSIN-mCherry-hPGK-GFP (providing the transgene vector), as previously described. 48 
hours post-transfection, cells were transferred into a 25 cm2 t-flask and puromycin selection was 
started (0.5 µg/ml; InvivoGen). Medium was regularly exchanged during 3 weeks, until the cells 
in the t-flask reached confluence after standard splitting dilutions (1:15 and 1:30) in the following 
3 or 4 days (respectively). A new antibiotic selection step was performed with blasticidin, 
hygromicin B and puromycin for one week. 
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3. Results 
 
3.1. Evaluation of T26S HIV-1 Protease for lentiviral vector production 
To minimize the cytotoxicity of the viral components for the development of a packaging 
cell line for stable lentiviral vector production, a point mutation was generated in the active site of 
the HIV-1 protease. This mutation consisted in changing amino acid 26 from a threonine to a 
serine (T26S)63. Konvalinka and co-workers reported that this mutation resulted in 5- to 10-fold 
reduction in the proteolytic activity compared to the WT HIV-1 protease and, consequently, lower 
protease-mediated cytotoxicity without effect on virus maturation and infectivity 63. In this work, 
we evaluated the use of the T26S HIV-1 protease to establish a stable cell line for lentiviral vector 
production. As control, an inactivating mutation was performed by changing amino acid 25 from 
an aspartic acid to an asparagine (D25N) 64. 
3.1.1. Proteolytic processing of Gag-Pro-Pol and Gag polyprotein by T26S HIV-1 protease 
To assess the ability of T26S HIV-1 protease to process Gag-Pro-Pol and Gag 
polypeptide, protein extracts from cells transfected with pMDLg/pRRE or its variants (WT, T26S 
and D25N) were analyzed by western blotting (Figure 3.1). 
 
 
 
 
 
 
 
Figure 3.1 – Analysis of Gag-Pro-Pol and Gag proteolytic processing by T26S HIV-1 
protease. A) Precursor proteins and cleavage products containing p24 peptide sequence (identified in 
grey). Grey arrows represent the cleavage sites for HIV-1 protease. MA: matrix; CA: capsid; NC: 
nucleocapsid; PR: protease; RT: reverse transcriptase; IN: integrase. B) Western blotting analysis of Gag-
Pro-Pol and Gag proteolytic processing by WT, T26S and D25N HIV-1 proteases. Extracts of HEK 293T 
cells transfected with pRSV-Rev and pMDLg/pRRE variants (WT, T26S and D25N) were analyzed by 
immunoblotting with anti-HIV-1 p24 antibody. Precursor proteins and cleavage products are identified on the 
left. WT: wild-type HIV-1 protease; T26S: T26S HIV-1 protease; D25N: D25N HIV-1 protease. 
 
T26S HIV-1 protease showed Gag-Pro-Pol and Gag polyprotein processing similar to the 
WT HIV-1 protease. As expected, D25N inactivating mutation yielded no Gag-Pro-Pol and Gag 
polyprotein processing. 
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3.1.2. Lentiviral vector particles production with T26S HIV-1 protease 
The main challenge for stable production of lentiviral vector is the cytotoxicity of the viral 
protease. According to Konvalinka and co-workers, the T26S mutation in the active site of the 
HIV-1 protease reduces its cytotoxic activity 63. However, the authors did not report the use of 
T26S HIV-1 protease for lentiviral vector production. 
To evaluate the ability of T26S HIV-1 protease to support lentiviral vector production, 
transient production with third generation lentiviral vector packaging 41 pseudotyped with VSV-G 
was performed and infectious and total particles were assessed (Figure 3.2). For total particles 
quantification, p24 ELISA was performed in viral supernatants. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 – Transient production of lentiviral vector with T26S HIV-1 protease. Infectious 
particles titers are shown as average ± standard deviation of twelve biological replicates (n=12) for the WT 
and T26S HIV-1 proteases, and three biological replicates (n=3) for D25N HIV-1 protease. The numbers on 
top of the bars indicate the ratio of infectious particles per total particles of twelve biological replicates (n=12). 
Detection limit of 4.0×104 I.P./ml is indicated by a dashed arrow. I.P.: infectious particles; WT: wild-type HIV-
1 protease; T26S: T26S HIV-1 protease; D25N: D25N HIV-1 protease, n.d.: not detected. 
 
Infectious vector titer was found to be similar between the WT and the T26S HIV-1 
protease (2 × 107 I.P./ml). Regarding total particles, T26S HIV-1 protease additionally showed a 
decreased ratio of infectious particles per total particles by approximately 2-fold. As expected, 
D25N HIV-1 protease yielded low infectious titer. Total particles were not detected in productions 
with D25N HIV-1 protease. 
Since it was not possible to access total particles quantification of lentiviral vectors 
produced with D25N HIV-1 protease with p24 ELISA, a parallel production was performed in 
serum-free conditions to enable total particles quantification by NTA (Nanosight® NS500) (Figure 
3.3). 
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Figure 3.3 – Total particles quantification of lentiviral vector with T26S HIV-1 protease by 
nanoparticle tracking analysis. Total particles values assessed using Nanosight® NS500 or p24 
ELISA are shown as average ± standard deviation of three and two technical replicates, respectively. T.P.: 
total particles; WT: wild-type HIV-1 protease; T26S: T26S HIV-1 protease; D25N: D25N HIV-1 protease; 
ELISA: enzyme-linked immunosorbent assay. 
   
Total particles quantified by NTA were similar between WT and T26S HIV-1 protease and 
higher values for D25N HIV-1 protease. These results suggest that p24 ELISA detects exclusively 
p24 in its processed form. 
3.1.3. Cytotoxicity assessment of T26S HIV-1 protease 
Our first trial to evaluate T26S HIV-1 protease-mediated cytotoxicity was by performing 
transient transfection of HEK 293T cells with pRSV-Rev and pMDLg/pRRE and its variants (WT, 
D25N and T26S). After 48 hours apoptosis was assessed using NucView™ 488 Caspase-3 
Substrate and MitoView™ 633 mitochondrial dye (Biotium Inc., Fremont, CA, USA). No 
differences between HIV-1 proteases or controls were observed (data not shown). We 
hypothesized that cytotoxicity would be more evident in long term culture not easily seen using a 
transient transfection. In this context, an expression cassette based on the tetracycline-inducible 
expression system 57 was constructed to assess the cytotoxicity of the T26S HIV-1 protease in 
HEK 293T during long term culture (Figure 3.4 and Figure A.1C from annexes).  
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Figure 3.4 – Inducible expression cassette constructed for HIV-1 protease induced gene 
expression. Orange and red arrow represents inducible and constitutive gene expression, respectively. 
BiTet: Bidirectional Tet-dependent; PminCMV: minimal Cytomegalovirus promoter; PGK: human 
phosphoglycerate kinase 1 promoter; TRE: Tetracycline responsive element; rtTA: reverse tetracycline 
transactivator (rtTA), zeocinR: zeocin resistance marker. 
 
We choose the available inducible system in our lab, bidirectional Tet-dependent 
promoter, to control the expression of T26S HIV-1 protease. In this system, doxycycline (a 
tetracycline analogue) binds to the reverse tetracycline transactivator (rtTA) protein, which is 
under the control of the BiTet promoter. The resulting rtTA protein is able to bind to DNA in the 
tetracycline responsive element (TRE), inducing the transcription of T26S HIV-1 protease gene 
and itself (Tet-on). In this way, T26S HIV-1 protease is expressed after addition of doxycycline to 
culture medium. In order to select cells transfected with the inducible T26S HIV-1 protease 
expression cassette, PGK promoter was introduced into the construction to allow constitutive 
expression of the zeocin resistance marker (zeocinR), enabling the selection of cells without 
induction of the protease expression. As control, WT and D25N HIV-1 protease inducible 
expression system were also developed. Subsequently, HEK 293T cells were transfected with 
the plasmids containing the inducible expression cassettes and selected as described in the 
Materials and Methods section. 
 To further investigate the protease-mediated cytotoxicity, HIV-1 protease gene 
expression was induced with 1 µg/ml doxycycline every 24 hours and cell growth was monitored 
(Figure 3.5). Additionally, RNA and protein extracts were performed 3 days after the first 
induction. 
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Figure 3.5 – Cell growth of HEK 293T expressing HIV-1 protease. The blue, red and green colors 
represent cells with inducible expression of WT, T26S and D25N HIV-1 proteases. Grey arrows indicate 
induction of HIV-1 proteases gene expression conducted with 1 µg/ml doxycycline. Error bars correspond to 
10% error for cell counting. WT: wild-type HIV-1 protease; T26S: T26S HIV-1 protease; D25N: D25N HIV-1 
protease. 
 
Cell growth was found to be similar between cells expressing the WT, T26S and D25N 
HIV-1 proteases. However, HIV-1 protease activity could not be detected in protein extracts (data 
not shown). Therefore, RT-qPCR was performed to evaluate gene expression of HIV-1 proteases 
with the bidirectional Tet-dependent promoter (Figure 3.6). Cells without induced expression 
were used as controls.  
 
 
 
 
 
 
 
 
Figure 3.6 – Gene expression of HIV-1 proteases under the control of a bidirectional Tet-
dependent promoter. White and grey bars correspond to gene expression without or with doxycycline 
induction, respectively. Gene expression was quantified after normalization to a control gene (RPL22) using 
the 2-ΔCT method as defined in Materials and Methods. Gene expression levels are show as average 
expression (relative to the control gene, RPL22) ± standard deviation of two technical replicates. WT: wild-
type HIV-1 protease; T26S: T26S HIV-1 protease; D25N: D25N HIV-1 protease; CT: crossing threshold. 
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For all the HIV-1 proteases, low gene expression with the BiTet promoter was observed. 
The judgment on the low expression levels related to the high CT (crossing threshold) values 
obtained (Table A.3 in annexes). 
To evaluate the functionality of the inducible expression system constructed, HEK 293T 
cells expressing egfp under the control of the BiTet promoter were established, similarly as 
described to previous cells with HIV-1 proteases. eGFP fluorescence intensity was assessed by 
flow cytometry (CyFlow® Space) after 3 days of continuous induction (Figure 3.7). Cells without 
induced egfp expression and HEK 293T were used as controls.  
 
 
 
 
 
 
 
 
Figure 3.7 – eGFP fluorescence intensity after induction with doxycycline. Blue, red and 
orange represents HEK 293T, selected cells without and with induction of eGPF gene expression, 
respectively. Positive cells for eGFP are indicated in “+” gate and negative cells in “-” gate. 1 and 2 indicate 
two different cell populations. Data was treated using FlowJo™ software. 
 
The results from Figure 3.7 showed that even without addition of doxycycline, egfp is 
expressed, revealing a leakiness feature of the bidirectional Tet-dependent promoter. Moreover, 
eGFP intensity increased only by 4-fold after induction with doxycycline. Additionally, two cells 
populations (referred as 1 and 2) are observed with the inducible eGFP expression cassette. 
Population 1 did not show eGFP intensity, suggesting that egfp is not being expressed even after 
induction. 
 
3.2. Lentiviral vector production with T26S HIV-1 protease and non-cytotoxic envelope 
glycoproteins 
VSV-G has been the envelope glycoprotein of choice for lentiviral vector production 
because of its wide tropism and stability conferred to viral particles 43. However, due to its 
cytotoxicity, it cannot be used to establish a packaging cell line for stable and constitutive 
production of lentiviral vectors. Moreover, non-toxic Gammaretrovirus envelope glycoproteins 
such as the amphotropic MLV 4070A, RD114 and GaLV envelope glycoproteins have been 
successfully used to pseudotype lentiviral vectors 45–50,61,67. 
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3.2.1. Evaluation of lentiviral vector production with T26S HIV-1 protease and retroviral 
envelope glycoproteins 
In this work, three plasmids were constructed for the 4070A, chimeric RD114 envelope 
glycoprotein with the cytoplasmic tail of 4070A (RD114A)45,46 and chimeric GaLV envelope 
glycoprotein with the cytoplasmic tail of 10A1 (GaLV10A1)49 (indicated with * in Figure 3.9). To 
eliminate possible expression bias, these envelopes were cloned in the same expression cassette 
(Figure A.1A in annexes). 
Transient production of lentiviral vectors with the T26S HIV-1 protease was performed to 
evaluate the titers of viral particles pseudotyped with the 4070A, RD114A and GaLV10A1 (Figure 
3.8). As control, WT HIV-1 protease was also used. For titration of infectious particles, two 
protocols were performed: standard procedure and spin inoculation. Both use polybrene (8 µg/ml) 
for vector titer enhancement, but spin inoculation has an additional step – centrifugal inoculation 
– to potentiate physical contact of viral particles with the target cells 61.  
 
 
 
 
 
 
 
 
 
 
Figure 3.8 – Lentiviral vector production with T26S HIV-1 protease and non-cytotoxic 
retroviral envelope glycoproteins. White and grey bars represent infectious titers obtained with 
standard protocol or spin inoculation, respectively. Values from standard protocol are shown as average ± 
standard deviation of two technical replicates. Values from spin inoculation are shown as average ± standard 
deviation of three biological replicates (n=3). The numbers on the top of the bars indicate fold change of 
infectious titer with the T26S HIV-1 protease, obtained by spin inoculation, relatively to the corresponding 
titer with the WT HIV-1 protease. Fold changes are shown for significant changes based on an one-tailed 
non-paired t-test, * p<0.1 and ** p<0.01. Detection limit of 4.0×104 I.P./ml is indicated by a dashed arrow. 
WT: wild-type HIV-1 protease; T26S: T26S HIV-1 protease; D25N: D25N HIV-1 protease; I.P.: infectious 
particles. 
 
For the three envelope glycoproteins evaluated, T26S HIV-1 protease yielded reduced 
titer relatively to the WT HIV-1 protease. This result was independent of the infection protocol 
used. 
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3.2.2. Engineering envelope glycoproteins for enhanced proteolytic processing 
Gammaretrovirus envelope glycoproteins, unlike VSV-G, undergo proteolytic processing 
during virion assembly mediated by the retroviral protease 68. In this step, a short sequence – R-
peptide – is cleaved from the cytoplasmic tail 68. This cleavage is required for virus entry, since it 
activates the fusogenic activity of the envelope glycoprotein 67–70. 
Since the R-peptide cleavage site in the original envelope glycoproteins was a retroviral 
sequence, better results were expected with a lentiviral cleavage site for lentiviral vector 
production, especially considering the putative reduced activity of the T26S HIV-1 protease. 
Therefore, the influence of the protease cleavage sequence on the R-peptide cleavage site and 
its impact on viral particles production was studied. To this end, cleavage sites recognizable by 
the HIV-1 protease were introduced in 4070A, RD114A and GaLV10A1. These envelope 
glycoproteins shared the retroviral cleavage site – VQAL↓VLTQ – of the cytoplasmic tail of 4070A. 
Herein, several envelope glycoproteins chimeras were constructed, engineered at the protease 
cleavage site of the R-peptide, to contain cleavage sequences amenable to HIV-1 proteolytic 
processing (Figure 3.9).  
For each envelope glycoprotein, three mutations were performed: 
 ΔR: the removal of the R-peptide, generating a truncated cytoplasmic tail 67,70; 
 pro: cleavage site sequence of HIV-1 matrix/capsid (MA/CA) – SQNY↓PIVQ; 
 giflet: synthetic cleavage site sequence reported as the most efficiently cleaved peptide 
site by the HIV-1 protease – GSGIF↓LETSL 66.  
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Figure 3.9 – Schematic representation of engineered envelope glycoproteins. On the top are 
represented the surface and transmembrane subunits and domains of the envelope glycoproteins: 
ectodomain, transmembrane domain (TMD) and cytoplasmic tail (CT). The blue, sky blue, green and orange 
bars represent sequences from 4070A, 10A1, RD114 and GaLV envelope glycoproteins, respectively. The 
square outlined in black is the R-peptide sequence. The white, yellow and red thunder-like shape represent 
the non modified, pro and giflet mutations on the protease cleavage site of the R-peptide, respectively. *: 
original envelope glycoproteins used to evaluate lentiviral vector production with T26S HIV-1 protease 
(Figure 3.8).  
 
The engineered envelope glycoproteins were evaluated in transient production of 
lentiviral vector using T26S HIV-1 protease (Figure 3.10). WT HIV-1 protease was used as 
control. Due to the number of viral samples to be assessed, total particles were quantified by p24 
ELISA. For titration of infectious particles, spin inoculation was performed.
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Figure 3.10 – Lentiviral vector production with T26S HIV-1 protease and engineered envelope glycoproteins. The bars correspond to infectious particles and 
the dots to total particles. The numbers on the top of the bars indicate fold increase of infectious titer relatively to the corresponding non modified envelope glycoprotein. All values 
are shown as average ± standard deviation of three biological replicates (n=3). Fold increase is shown for significant changes based on a one-tailed non-paired t-test, * p<0.1 
and ** p<0.01. Detection limit of 4.0×104 I.P./ml is indicated by a dashed arrow. WT: wild-type HIV-1 protease; T26S: T26S HIV-1 protease.
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Mutations in the R-peptide cleavage site were found not to increase infectious titers of 
lentiviral vectors pseudotyped with 4070A and RD114A, with the exception of the RD114Apro. 
However, all mutations increased viral titers of GaLV10A1. Remarkably, ΔR mutation in 
GaLV10A1 envelope glycoprotein exhibited the highest viral titer (around 6 × 106 IP/ml), 
increasing the infectious particles yields by 36.7-fold. This effect was also visible with the WT HIV-
1 protease, with a 4.9-fold improvement.  
 
3.2.3. Effect of engineered envelope glycoproteins on producer cell 
The results obtained with the engineered envelopes, particularly with GaLV10A1, 
encourage their use for the establishment of stable cell lines for lentiviral vector production. 
However, some of the engineered envelopes were expectably cytotoxic, namely those with the 
ΔR mutation, leading to the syncytium formation. Syncytium are multi-nucleate enlarged cells 
formed by fusion of an infected cells with neighboring cells. This event is induced by viral proteins 
expressed at cell surface that are directly fusogenic at the host cell membrane (Figure 3.11) 
 
Figure 3.11 – Syncytium formation induced by surface expression of a viral fusogenic 
protein. Retrieved from ViralZone. http://viralzone.expasy.org/all_by_species/5957.html (Accessed: 30th 
June 2016). 
 
To evaluate syncytium formation, cells were transfected with the plasmids coding for the 
engineered envelope glycoproteins. VSV-G and cells not expressing envelope glycoproteins were 
used as controls. 24 hours post transfection, cells were observed by phase-contrast microscopy 
(Figure 3.12).  
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Figure 3.12 – Syncytium formation in HEK 293T cells expressing engineered envelope 
glycoproteins. Scale bar: 45 µm. 
 
As expected, GaLV10A1ΔR and RD114AΔR induced syncytium formation. Additionally, 
RD114Apro expression also led to syncytium formation but less noteworthy. However, and 
contrarily to what could be expected, syncytium formation was not observed in cells expressing 
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4070AΔR. Syncytium formation is mediated by the interaction of the envelope glycoproteins 
present at the cell membrane with neighboring cell’s specific surface receptors, leading to cells 
fusion. Since syncytium formation was not observed in cells expressing 4070AΔR, we 
hypothesized that the cell surface receptor for 4070A was not expressed or expressed at low 
levels. Thus, gene expression of cell surface receptors for 4070A, RD114A and GaLV10A1 – 
SLC20A2, SLC1A5 and SLC20A1, respectively 71 – in HEK 293T cells was assessed by RT-
qPCR (Figure 3.13).  
 
 
 
 
 
 
 
Figure 3.13 – Gene expression of cell surface receptors for envelope glycoproteins in HEK 
293T cell line. SLC20A2, SLC1A5 and SLC20A1 are the cell surface receptors for 4070A, RD114A and 
GaLV10A1, respectively. Gene expression was quantified after normalization to a control gene (RPL22) 
using the 2-ΔCT method as defined in Materials and Methods. Gene expression levels are shown as average 
expression (relative to the control gene, RPL22) ± standard deviation of two technical replicates. 
 
Indeed, cell surface receptors expression showed significantly lower values of SLC20A2 
compared to SLC1A5 and SLC20A1. This results demonstrated that syncytium formation induced 
by an envelope glycoprotein is correlated with the expression of its specific cell surface receptor. 
More importantly, they open the door for the use of some of the newly engineered and high-titer 
envelope glycoproteins, namely GaLV10A1ΔR in stable producer cell by receptor knock out 
strategy. 
 
3.3. Establishment of stable producer cell lines for lentiviral vector production with T26S 
HIV-1 protease 
HEK 293T cell line constitutively expressing HIV-1 gag-pol with T26S mutation and rev, 
developed by Hélio Tomás (ACT Unit IBET/ITQB NOVA), was used as cell substrate to establish 
stable cell lines for lentiviral vector production with T26S HIV-1 protease and engineered envelope 
glycoproteins. Cells were transfected with pRRLSIN-mCherry-hPGK-GFP and selected as 
described in the Materials and Methods section. At this moment, we have successfully established 
a stable cell line expressing all the necessary components for lentiviral vector production, with the 
exception of the envelope glycoprotein. 
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4. Discussion and Conclusions 
 
The use of lentiviral vectors in gene therapy clinical trials, particularly those derived from 
HIV-1, has been growing due their unique ability to transduce and permanently modify non-
dividing cells 21, a feature that distinguishes them from their simple counterparts, gammaretroviral 
vectors. Additionally, lentiviral vectors show a safer integration pattern, with reduced oncogenic 
risk compared to retroviral vectors 22, and a more efficiently transduction of hematopoietic stem 
cells 21,72. These vectors offer a great promise for gene therapy, and are likely to overtake 
gammaretroviral vectors in clinical trials. To take advantage of the full potential of lentiviral vectors 
for gene therapy applications and aid a faster clinical to market transition, robust and standardized 
means for the production of these vectors are needed. In this context, the use of stable producer 
cell lines is of great value. However, the establishment of stable producer cell lines for lentiviral 
vector production has been hampered by the cytotoxicity of some viral components, namely the 
viral protease 54,55. In this thesis, we aimed at minimizing the cytotoxicity induced by the viral 
components in lentiviral vector production. Thus, a point mutation in the active site of the HIV-1 
protease was generated, changing amino acid 26 from a threonine to a serine (T26S) 63. This 
mutation is reported to reduce proteolytic activity compared to the WT protease by 5- to 10-fold, 
and yield lower protease-mediated cytotoxicity without affecting virus maturation and infectivity. 
Therefore, we evaluated lentiviral vector production with T26S HIV-1 protease.  
T26S HIV-1 protease showed similar Gag-Pro-Pol and Gag polypeptide proteolytic 
processing (Figure 3.1) and infectious titer yield (2 × 107 I.P./ml) similar to the WT HIV-1 protease 
in a transient production system with third generation lentiviral vector packaging (Figure 3.2). 
These results indicate that T26S HIV-1 protease proteolytic activity is sufficient to generate 
mature viral proteins, an essential step for viral infectivity64. However, a 2-fold decrease ratio of 
infectious particles per total particles was obtained with T26S HIV-1 protease comparing to the 
WT HIV-1 protease (Figure 3.2), decreasing the quality of LV preparation. This effect could be 
related to the putative reduced cytotoxicity of T26S HIV-1 protease that leads to an increment in 
the production of total particles (Figure 3.3), however, with less mature (infectious) particles due 
to the reduced proteolytic activity. This reduction in viral preparation quality was small and should 
be possible to improve by means of optimizing the stoichiometry of viral components for transient 
transfection production 73. More importantly, we have demonstrated for the first time that T26S 
HIV-1 protease can be used to produce lentiviral vectors with similar titers to the WT HIV-1 
protease in a transient transfection system, making it a great candidate for the establishment of 
a novel stable packaging cell line for continuous LV production. 
To study the protease-mediated cytotoxicity, we hypothesized that cytotoxicity would be 
more evident in long term culture, being a stable cell line the best approach to express the HIV-1 
protease and evaluate its cytotoxicity. Instead of a constitutive expression cassette to express the 
HIV-1 protease, an inducible expression cassette was chosen since stable expression could 
provide a proliferative advantage to cells with lower HIV-1 protease gene expression. This could 
bias a fair comparison between the WT HIV-1 protease and its reduced activity mutant T26S. 
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Therefore, a tetracycline inducible expression promoter (BiTet promoter) was used to control HIV-
1 protease gene expression and zeocin selective marker was put under the control of a 
constitutive promoter (PGK) (Figure 3.4). With this system, HIV-1 protease is expressed only 
after addition of doxycycline in the culture medium (Tet-on), enabling the selection of cells 
transfected without its expression.  
After induction with doxycycline, there was no differences in the cell growth profile 
between cells expressing WT, T26S or D25N HIV-1 proteases (Figure 3.5), providing low 
evidence of any cytotoxicity. However, HIV-1 protease activity could not be detected in protein 
extracts (data not shown) and gene expression values were found to be low (Figure 3.6). 
Additionally, a small 4-fold increase was shown for eGFP intensity after induction of gene 
expression with the constructed inducible expression cassette (Figure 3.7). These results 
indicate that the inducible expression cassette did not induce gene expression at sufficiently high 
levels to assess HIV-1 protease-mediated cytotoxicity. Moreover, the leaky expression observed 
for the inducible expression cassette (Figure 3.7) is an undesirable feature of the system for the 
study of cytotoxic proteins, since it could have given proliferative advantage to cells with low copy 
number of integrated cassettes or integrated into inactive heterochromatin. This effect would 
result in little or no gene expression controlled by the weak BiTet promoter, but it would be enough 
to express the zeocinR under the control of the PGK promoter at necessary levels to confer 
antibiotic resistance during cell selection. In order to prevent this possible effect, a tighter control 
of gene expression is required. Therefore, optimization of the inducible expression cassette for 
HIV-1 proteases expression is ongoing by replacing the BiTet promoter with a stronger and tighter 
unidirectional doxycycline inducible Tet-On promoter, with the rtTA protein being provided in 
trans. 
Despite the fact that T26S HIV-1 protease provided infectious titer yields similar to WT 
HIV-1 protease (Figure 3.2), the envelope glycoprotein used – VSV-G – was cytotoxic 56, making 
it impossible to use it to establish stable cell lines for continuous lentiviral vector production. To 
overcome this limitation, non-toxic Gammaretrovirus envelope glycoproteins, commonly used in 
retroviral vector stable cell line development 17, have been used to pseudotype lentiviral vectors 
45–49,61,67. In line, we evaluated transient LV production with the Gammaretrovirus envelope 
glycoproteins 4070A, RD114A and GaLV10A1 (indicated with * in Figure 3.9). However, these 
envelope glycoproteins require cleavage of the R-peptide from the cytoplasmic tail of TM subunit, 
catalyzed by the viral protease, to activate the fusogenic activity necessary for virus entry 67–70. 
Due to the described reduced proteolytic activity 63, the conjugation of T26S HIV-1 protease with 
4070A, RD114A and GaLV10A1 could result in reduced titers compared to the WT HIV-1 
protease. This was in fact, observed (Figure 3.8), while for VSV-G, which does not require 
proteolytic processing for viral infectivity, reduced protease activity did not impact vector titers 
(Figure 3.2). Furthermore, the envelope glycoproteins used herein (4070A, RD114A and 
GaLV10A1) shared the same retroviral R-peptide cleavage site, which was hypothesized to be 
cleaved less efficiently by the HIV-1 protease, especially considering the putative reduced 
proteolytic activity of the T26S HIV-1 protease. Therefore, the retroviral cleavage site was 
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replaced by that of HIV MA/CA (pro mutation) or by a synthetic cleavage sequence (giflet 
mutation) efficiently cleaved by HIV-1 protease (Figure 3.9). As a control, the proteolytic 
processing required for fusogenic activity of Gammaretrovirus envelope glycoproteins was 
obliterated by removing the R-peptide from the cytoplasmic tail (ΔR mutation). This control 
allowed to establish the maximum titer that could be obtained with each of the envelope 
glycoproteins if no proteolytic processing was needed. 
Engineering R-peptide cleavage site did not result in increased infectious titers with 
4070A and RD114A, with the exception of a small 1.5-fold increase with RD114Apro (Figure 3.10). 
Previous work has shown that the pro mutation enhances cleavage interactions between HIV-1 
protease and the RD114 cytoplasmic tail during virion formation 47. Thus, a higher fold increase 
was expected with the most efficiently cleaved sequence 66 – giflet mutation – than the pro 
mutation, which was not observed. RD114Apro also induced unexpected syncytium formation in 
cells transfected with its encoding plasmid (Figure 3.12). A possible explanation for these results 
is that the pro mutation could have led to conformational changes in the TM subunit that modified 
its folding, making it susceptible to proteolytic processing by cellular proteases and, consequently, 
leading to syncytium formation and a minor increase in infectious titer yield. Nevertheless, 
considering the small fold increase for RD114Apro and no increased titers for the rest of 
engineered R-peptide cleavage sites in RD114A and 4070A, the results indicate that proteolytic 
processing of these envelope glycoproteins was not hampering lentiviral vector production with 
T26S HIV-1 protease. 
Regarding GaLV10A1, engineered R-peptide cleavage sites allowed rescuing infectious 
viral titers produced with T26S HIV-1 protease to similar levels of those obtained with the WT 
HIV-1 protease (Figure 3.10). Moreover, engineered R-peptide cleavage sites increased 
infectious particles production compared to the original retroviral cleavage sequence with both 
WT and T26S HIV-1 protease to similar values. This supports that insufficiently proteolytic 
processing of GaLV10A1 was hampering viral vector infectivity when using T26S HIV-1 protease. 
The highest infectious titer was achieved with GaLV10A1ΔR (around 6 × 106 I.P./ml). These titers 
are very competitive considering those typically obtained with the highest titer envelope 
glycoprotein used in LV production, VSV-G. Although increasing infectious particles by 36.7-fold, 
GaLV10A1ΔR is not suitable for the establishment of a continuous stable cell line for LV production, 
due to induced syncytium formation in HEK 293T cells expressing this envelope glycoprotein 
(Figure 3.12). Yet, it would be possible to develop a conditional packaging cell line, where an 
inducible promoter would control GaLV10A1ΔR expression. Additionally, GaLV10A1ΔR can be 
used in transient transfection production of lentiviral vectors replacing the commonly used 
pantropic VSV-G, offering a more specific tropism for in vivo gene therapy applications, especially 
to hematopoietic stem cells 50. GaLV10A1giflet was found to be the best candidate for stable cell 
line development, with a 19.8-fold increase for the T26S HIV-1 protease. GaLV10A1giflet is also of 
interest for the development of packaging cell lines using WT HIV-1 protease, since a 2.5-fold 
increase was observed when compared to the non modified GaLV10A1. Nevertheless, better 
results are expected with packaging cell lines expressing T26S HIV-1 protease, since its putative 
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reduced cytotoxic activity would possibly allow constitutive HIV-1 gag-pol expression at a high 
level compared to WT HIV-1 protease. 
Several studies have shown that deletion of the R-peptide from the cytoplasmic tail of 
Gammaretrovirus envelope glycoproteins induces syncytium formation 67,70. Surprisingly, this 
event was not observed in HEK 293T cells expressing 4070AΔR envelope glycoprotein, unlike 
RD114AΔR and GaLV10A1ΔR (Figure 3.12). Therefore, gene expression of cell surface receptors 
specific to 4070A, RD114A and GaLV10A1 envelope glycoprotein (SLC20A2, SLC5A1 and 
SLC20A1, respectively) was assessed (Figure 3.13). Gene expression quantification suggested 
that 4070A did not induce syncytium formation due to low expression of its cell surface receptor, 
SLC20A2. This observation strongly encourages the use of the high-titer GaLV10A1ΔR for the 
establishment of a novel stable packaging cell line for continuous LV production using cell 
substrates with SLC20A1 knock out. This could be achieved using genome editing tools, namely 
the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated 
protein Cas9 (CRISPR-Cas9) technology. Because of its simplicity and high efficiency, CRISPR-
Cas9 has became the most commonly used tool for genome editing and has been proven possible 
to modify endogenous genes in a wide range of cells and organisms 74,75. Therefore, this genome 
editing tool will be used in the follow-up of this work to knock out the cell surface receptor of 
GaLV10A1 in HEK 293T, in order to establish a novel stable packaging cell line for continuous 
LV production, using the newly engineered high-titer GaLV10A1ΔR and the T26S HIV-1 protease. 
The establishment of stable producer cell lines with T26S HIV-1 protease is ongoing. 
Currently, we have successfully developed stable cell lines expressing all the viral components 
required for lentiviral vector production, with the exception of the envelope glycoprotein. The 
highest mCherry (transgene) yielding clones population will be isolated and transfected with the 
plasmids encoding envelope glycoproteins, with the exception of those that induced syncytium 
formation. The resulting stable producer cells will allow the evaluation of lentiviral vector titers 
with the engineered envelope glycoproteins conjugated with the T26S HIV-1 protease in a stable 
continuous production approach. Considering the higher titer of 4070A compared to all envelope 
glycoproteins tested in transient production (Figure 3.8 and 3.10), the same result is expected in 
a stable production system. Yet, several studies have shown that GaLV envelope glycoproteins 
transduce more efficiently certain human cell types than 4070A 76–78, despite showing a lower 
titer. This observation is of particular interest for in vivo gene transfer applications. 
In this work, the potential of T26S HIV-1 protease was evaluated and validated for 
lentiviral vector production. Additionally, engineered envelope glycoproteins were established 
which, combined with the possibility of genome editing of producer cells, open new possibilities 
for the establishment of continuous LV production systems. Moreover, lentiviral vectors 
pseudotyped with the engineered GaLV10A1 will offer a specific tropism to hematopoietic stem 
cells, which are attractive targets for lentiviral gene transfer in vivo gene therapy applications. 
Thus, this work contributes directly to the development of a novel packaging cell line for the 
constitutive production of lentiviral vectors for gene therapy, by evaluating for the first time the 
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use of a less toxic HIV-1 protease and by providing novel chimeric envelope glycoproteins 
providing increased titers. 
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Annexes 
Table A.1 – Primers and templates for plasmids construction. 
Construct 
Insert Vector 
Fragment Source Primers or Restriction Enzymes Parental Primers or Restriction Enzymes 
pCMV-4070A 4070a pMonoZeo-4070A 
F - TTTTGGCAAAGAATTCATGGCGCGTTCAACG 
phGaLV10A1 
EcoRI 
KasI 
R - GTCAACACTAGGCGCCTATGGCTCGTACTC 
pCMV-RD114A RD114a pLTR-RD114A 
F - TTTTGGCAAAGAATTCATGAAACTCCCAACA 
R - GTCAACACTAGGCGCCTCATGGCTCGTACTC 
pCMV-GaLV10A1 - - - 
F - TTTGGCAAAGAATTCATGGTATTGCTGCCTGG 
R - GAATTCTTTGCCAAAATGATG 
pCMV-4070AΔR - - - 
pCMV-4070A 
F - GTGGTCCAGGCTCTATAGGCGCCTAGTGTTGACAATTAATC 
R - TAGAGCCTGGACCACTGATATCC 
pCMV-4070Apro - - - 
F - CAAAATTACCCTATAGTGCAACAATATCACCAGCTGAAGC 
R - TATAGGGTAATTTTGGCTCACTGATATCCTGTCTTTAACAAATTG 
pCMV-4070Agiflet - - - 
F1 - CTGGAAACCAGCCTGCAATATCACCAGCTGAAGCC 
R1 - CAGGCTGGTTTCCAGAGCCTGGACCACTGATATCC 
F2 - GGCAGCGGCATCTTCCTGGAAACCAGCCTGCAATATC 
R2 - GAAGATGCCGCTGCCCACTGATATCCTGTCTTTAACAAATTG 
pCMV-RD114AΔR - - - 
pCMV-RD114A 
F - GTGGTCCAGGCTCTGTGAGGCGCCTAGTGTTGAC 
R - CAGAGCCTGGACCACTGAG 
pCMV-RD114Apro - - - 
F - CAAAATTACCCTATAGTGCAGCAATATCACCAGCTAAAAC 
R - TATAGGGTAATTTTGGCTCACTGAGATCCTGTCTTTAAC 
pCMV-RD114Agiflet - - - 
F1 - CTGGAAACCAGCCTGCAATATCACCAGCTAAAACCC 
R1 - CAGGCTGGTTTCCAGAGCCTGGACCACTGAGATC 
F2 - GGCAGCGGCATCTTCCTGGAAACCAGCCTGCAATATC 
R2 - GAAGATGCCGCTGCCCACTGAGATCCTGTCTTTAACAAATTG 
pCMV-GaLV10A1ΔR - - - 
pCMV-GaLV10A1 
F - GTAGTCCAGGCTTTATAGGGCGCCTAGTGTTGAC 
R - TAAAGCCTGGACTACTGAGATCC 
pCMV-GaLV10A1pro - - - 
F - CAAAATTACCCTATAGTGCAACAATACCACCAGCTAAAGC 
R - TATAGGGTAATTTTGGCTTACTGAGATCCTGTCTTTAACAAATTG 
pCMV-GaLV10A1giflet - - - 
F1 - CTGGAAACCAGCCTGCAATACCACCAGCTAAAGCC 
R1 - CAGGCTGGTTTCCAGAGCCTGGACTACTGAGATCC 
F2 - GGCAGCGGCATCTTCCTGGAAACCAGCCTGCAATACC 
R2 - GAAGATGCCGCTGCCTACTGAGATCCTGTCTTTAACAAATTGAAC 
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Table A.1 – Primers and templates for plasmids construction (continued). 
Construct 
Insert Vector 
Fragment Source Primers or Restriction Enzymes Parental Primers or Restriction Enzymes 
pTet-GFP 
egfp 
pRRLSIN.cPPT.PGK-
GFP.WPRE 
F - TTTGGCAAAGAATTCATGGTGAGCAAGGGC 
phGaLV10A1 
F1 - GAATTCTAGTGTTGACAATTA 
R - TCAACACTAGAATTCTTACTTGTACAGCTC R1 - GAATTCTTTGCCAAAATG 
PGK 
promoter 
F - AAGTAAGAATTCTAGCCACGGGGTTGGGGT F2 - CTCACTATAGGAGGGCC 
R - CCCTCCTATAGTGAGCCTGGGGAGAGAGGT R2 - CTAGAATTCTTACTTGTACAGC 
BiTet 
Promoter 
pTargLox-
polyATetVSV-G-
FerHprom 
BamHI 
F3 - GAGTTCGAATGCTAGATTTTGGCAAAGAATTCATGG 
R3 - AACTAAGTAAGGATCCTAGGTGCACTCTCAGTACAATC 
pTet-HIV1 
PRWT/PGK-Zeo 
HIV-1 PR pMDLg/pRRE 
F - TGGTTTAAACGAATTCATGCCTCAGATCACTCTTTGGCAGC 
R - CCCGTGGCTAGAATTCTTATTAAAAATTTAAAGTGCAGCCAATCTGAGTC 
pTet-GFP EcoRI 
pTet-HIV1 
PRT26S/PGK-
Zeo 
HIV-1 
PRT26S 
pMDLg/pRRET26s 
pTet-HIV1 
PRD25N/PGK-
Zeo 
HIV-1 
PRD25N 
pMDLg/pRRED25N 
 
 
 
 
 
 
 
 
 
Figure A.1 – Plasmids constructs. A) Plasmid used to encode several envelope glycoproteins. B) Plasmid with inducible expression cassette encoding eGFP. C) 
Plasmid with inducible expression cassette encoding HIV-1 protease (WT, T26S and D25N).
A) B) C) 
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Table A.2 – Primers for RT-qPCR. 
Gene Primers (5’  3’ sequence) 
SLC20A2 F - CCCCAGAGGACAGTGAGAAG 
R - GGAAATGGAACAGGAGGTGA  
SLC1A5 F - TACATTCTGTGCTGCCTGCT 
R - ATGAAACGGCTGATGTGCTT 
SLC20A1 F - GGCAGAGATGGGTCTAGGTG 
R - TTGGTGTTGCCACTTTTGAA 
HIV-1 protease F - TTTGCCAGGAAGATGGAAAC 
R - TGCAGCCAATCTGAGTCAAC 
RPL22 F - CTGCCAATTTTGAGCAGTTT 
R - CTTTGCTGTTAGCAACTACGC 
 
 
Table A.3 – Crosing thresholds (CT) obtained from the RT-qPCR of the inducible 
expression cassette for HIV-1 proteases. 
HIV-1 protease WT T26S D25N 
Induction - + - + - + 
CT* 28.61 23.90 26.66 24.78 29.05 25.45 
RPL22 CT* 19.84 19.97 20.13 20.00 19.94 20.12 
* Average CT of 2 technical replicates 
 
 
 
 
